Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 675 of 2051 entries
View as:

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Phase: N/A Priority: Normal
NCT ID: NCT05468697 Org: User:
Start: 08/10/22 End: 07/21/26 Due: 07/21/27

Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)

Phase: N/A Priority: Normal
NCT ID: NCT01463683 Org: User:
Start: 11/29/11 End: 11/06/12 Due: 11/06/13

A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00092846 Org: User:
Start: 12/04/02 End: - Due: -

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Phase: N/A Priority: Normal
NCT ID: NCT01274559 Org: User:
Start: 03/01/11 End: 02/26/13 Due: 02/26/14

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

Phase: N/A Priority: Normal
NCT ID: NCT02576990 Org: User:
Start: 12/02/15 End: 10/23/20 Due: 10/23/21

Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)

Phase: N/A Priority: Normal
NCT ID: NCT03482713 Org: User:
Start: 03/16/18 End: 06/07/18 Due: 06/07/19

Safety Study of ProQuad® rHA in Infants (V221-037)

Phase: N/A Priority: Normal
NCT ID: NCT00560755 Org: User:
Start: 10/24/07 End: 11/24/08 Due: 11/24/09

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

Phase: N/A Priority: Normal
NCT ID: NCT03918278 Org: User:
Start: 06/19/19 End: 06/09/25 Due: 06/09/26

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Phase: N/A Priority: Normal
NCT ID: NCT04165096 Org: User:
Start: 01/21/20 End: 05/28/25 Due: 05/28/26

A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06816043 Org: User:
Start: 02/21/25 End: 06/17/25 Due: 06/17/26

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Phase: N/A Priority: Normal
NCT ID: NCT06780098 Org: User:
Start: 05/28/25 End: 03/02/32 Due: 03/02/33

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Phase: N/A Priority: Normal
NCT ID: NCT06818643 Org: User:
Start: 03/25/25 End: 01/28/28 Due: 01/28/29

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Phase: N/A Priority: Normal
NCT ID: NCT06863272 Org: User:
Start: 06/25/25 End: 02/24/30 Due: 02/24/31

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Phase: N/A Priority: Normal
NCT ID: NCT06099782 Org: User:
Start: 12/26/23 End: 11/16/26 Due: 11/16/27

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

Phase: N/A Priority: Normal
NCT ID: NCT00293267 Org: User:
Start: 02/28/06 End: 05/31/11 Due: 05/31/12

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Phase: N/A Priority: Normal
NCT ID: NCT01451619 Org: User:
Start: 11/30/11 End: 04/30/12 Due: 04/30/13

MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00888355 Org: User:
Start: 05/31/92 End: 02/28/93 Due: 02/28/94

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

Phase: N/A Priority: Normal
NCT ID: NCT02054806 Org: User:
Start: 02/17/14 End: 04/30/21 Due: 04/30/22

A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

Phase: N/A Priority: Normal
NCT ID: NCT00888238 Org: User:
Start: 05/12/09 End: 07/21/09 Due: 07/21/10

Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)

Phase: N/A Priority: Normal
NCT ID: NCT03336502 Org: User:
Start: 12/20/17 End: 11/26/18 Due: 11/26/19

A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009)

Phase: N/A Priority: Normal
NCT ID: NCT00242476 Org: User:
Start: 09/30/05 End: 07/31/06 Due: 07/31/07

Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)

Phase: N/A Priority: Normal
NCT ID: NCT01097629 Org: User:
Start: 05/03/10 End: 11/08/11 Due: 11/08/12

A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)

Phase: N/A Priority: Normal
NCT ID: NCT04676425 Org: User:
Start: 03/17/21 End: 01/25/22 Due: 01/25/23

A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)

Phase: N/A Priority: Normal
NCT ID: NCT00379951 Org: User:
Start: 06/30/05 End: 05/31/06 Due: 05/31/07

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Phase: N/A Priority: Normal
NCT ID: NCT02180061 Org: User:
Start: 07/15/14 End: 08/31/17 Due: 08/31/18